Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free GXAI Stock Alerts

Gaxos.ai (GXAI) Competitors

Gaxos.ai logo
$0.83 -0.43 (-34.13%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$0.83 0.00 (-0.48%)
As of 08/14/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

GXAI vs. MGRX, BMGL, AIDX, NIVF, and IVF

Should you buy Gaxos.ai stock or one of its competitors? Gaxos.ai's main competitors and comparable companies include Mangoceuticals (MGRX), Basel Medical Group (BMGL), 20/20 Biolabs (AIDX), NewGenIvf Group (NIVF), and INVO Fertility (IVF). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Gaxos.ai compare to Mangoceuticals?

Gaxos.ai (NASDAQ:GXAI) and Mangoceuticals (NASDAQ:MGRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

Gaxos.ai has higher revenue and earnings than Mangoceuticals. Gaxos.ai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gaxos.ai$3.72M1.59-$3.90M-$0.50N/A
Mangoceuticals$460K19.95-$20.64M-$1.49N/A

42.6% of Gaxos.ai shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by company insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Gaxos.ai has a net margin of -64.81% compared to Mangoceuticals' net margin of -4,794.60%. Gaxos.ai's return on equity of -38.79% beat Mangoceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Gaxos.ai-64.81% -38.79% -36.99%
Mangoceuticals -4,794.60%-92.68%-87.43%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gaxos.ai
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Mangoceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Gaxos.ai had 6 more articles in the media than Mangoceuticals. MarketBeat recorded 11 mentions for Gaxos.ai and 5 mentions for Mangoceuticals. Gaxos.ai's average media sentiment score of 0.95 beat Mangoceuticals' score of 0.23 indicating that Gaxos.ai is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gaxos.ai
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Mangoceuticals
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Gaxos.ai has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Mangoceuticals has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market.

Summary

Gaxos.ai beats Mangoceuticals on 8 of the 13 factors compared between the two stocks.

How does Gaxos.ai compare to Basel Medical Group?

Gaxos.ai (NASDAQ:GXAI) and Basel Medical Group (NASDAQ:BMGL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

42.6% of Gaxos.ai shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Gaxos.ai had 7 more articles in the media than Basel Medical Group. MarketBeat recorded 11 mentions for Gaxos.ai and 4 mentions for Basel Medical Group. Gaxos.ai's average media sentiment score of 0.95 beat Basel Medical Group's score of 0.89 indicating that Gaxos.ai is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gaxos.ai
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Basel Medical Group
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Gaxos.ai has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Basel Medical Group has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Gaxos.ai has higher earnings, but lower revenue than Basel Medical Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gaxos.ai$3.72M1.59-$3.90M-$0.50N/A
Basel Medical Group$8.90M0.94-$9.50MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gaxos.ai
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Basel Medical Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Basel Medical Group has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. Basel Medical Group's return on equity of 0.00% beat Gaxos.ai's return on equity.

Company Net Margins Return on Equity Return on Assets
Gaxos.ai-64.81% -38.79% -36.99%
Basel Medical Group N/A N/A N/A

Summary

Gaxos.ai beats Basel Medical Group on 7 of the 11 factors compared between the two stocks.

How does Gaxos.ai compare to 20/20 Biolabs?

20/20 Biolabs (NASDAQ:AIDX) and Gaxos.ai (NASDAQ:GXAI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.

20/20 Biolabs has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. 20/20 Biolabs' return on equity of 0.00% beat Gaxos.ai's return on equity.

Company Net Margins Return on Equity Return on Assets
20/20 BiolabsN/A N/A N/A
Gaxos.ai -64.81%-38.79%-36.99%

42.6% of Gaxos.ai shares are owned by institutional investors. 29.8% of 20/20 Biolabs shares are owned by insiders. Comparatively, 3.2% of Gaxos.ai shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

20/20 Biolabs has higher earnings, but lower revenue than Gaxos.ai. 20/20 Biolabs is trading at a lower price-to-earnings ratio than Gaxos.ai, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
20/20 Biolabs$1.84M3.65-$3.74M-$0.28N/A
Gaxos.ai$3.72M1.59-$3.90M-$0.50N/A

20/20 Biolabs currently has a consensus price target of $5.00, suggesting a potential upside of 810.75%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, equities analysts plainly believe 20/20 Biolabs is more favorable than Gaxos.ai.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Gaxos.ai
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Gaxos.ai had 8 more articles in the media than 20/20 Biolabs. MarketBeat recorded 11 mentions for Gaxos.ai and 3 mentions for 20/20 Biolabs. 20/20 Biolabs' average media sentiment score of 1.43 beat Gaxos.ai's score of 0.95 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company Overall Sentiment
20/20 Biolabs Positive
Gaxos.ai Positive

Summary

20/20 Biolabs beats Gaxos.ai on 11 of the 15 factors compared between the two stocks.

How does Gaxos.ai compare to NewGenIvf Group?

Gaxos.ai (NASDAQ:GXAI) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

42.6% of Gaxos.ai shares are owned by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are owned by institutional investors. 3.2% of Gaxos.ai shares are owned by insiders. Comparatively, 31.8% of NewGenIvf Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NewGenIvf Group has a net margin of 0.00% compared to Gaxos.ai's net margin of -64.81%. NewGenIvf Group's return on equity of 0.00% beat Gaxos.ai's return on equity.

Company Net Margins Return on Equity Return on Assets
Gaxos.ai-64.81% -38.79% -36.99%
NewGenIvf Group N/A N/A N/A

NewGenIvf Group has higher revenue and earnings than Gaxos.ai.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gaxos.ai$3.72M1.59-$3.90M-$0.50N/A
NewGenIvf Group$4.73M0.73$9.88MN/AN/A

In the previous week, Gaxos.ai had 9 more articles in the media than NewGenIvf Group. MarketBeat recorded 11 mentions for Gaxos.ai and 2 mentions for NewGenIvf Group. NewGenIvf Group's average media sentiment score of 1.44 beat Gaxos.ai's score of 0.95 indicating that NewGenIvf Group is being referred to more favorably in the news media.

Company Overall Sentiment
Gaxos.ai Positive
NewGenIvf Group Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gaxos.ai
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
NewGenIvf Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Gaxos.ai has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, NewGenIvf Group has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

Summary

NewGenIvf Group beats Gaxos.ai on 8 of the 11 factors compared between the two stocks.

How does Gaxos.ai compare to INVO Fertility?

INVO Fertility (NASDAQ:IVF) and Gaxos.ai (NASDAQ:GXAI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Gaxos.ai has lower revenue, but higher earnings than INVO Fertility. Gaxos.ai is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INVO Fertility$7.22M0.31-$25.13M-$352.18N/A
Gaxos.ai$3.72M1.59-$3.90M-$0.50N/A

INVO Fertility currently has a consensus price target of $20.00, suggesting a potential upside of 1,958.46%. Given INVO Fertility's stronger consensus rating and higher probable upside, equities analysts plainly believe INVO Fertility is more favorable than Gaxos.ai.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INVO Fertility
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50
Gaxos.ai
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

12.0% of INVO Fertility shares are held by institutional investors. Comparatively, 42.6% of Gaxos.ai shares are held by institutional investors. 0.4% of INVO Fertility shares are held by company insiders. Comparatively, 3.2% of Gaxos.ai shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Gaxos.ai has a net margin of -64.81% compared to INVO Fertility's net margin of -183.75%. Gaxos.ai's return on equity of -38.79% beat INVO Fertility's return on equity.

Company Net Margins Return on Equity Return on Assets
INVO Fertility-183.75% -420.62% -45.21%
Gaxos.ai -64.81%-38.79%-36.99%

INVO Fertility has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market. Comparatively, Gaxos.ai has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

In the previous week, Gaxos.ai had 9 more articles in the media than INVO Fertility. MarketBeat recorded 11 mentions for Gaxos.ai and 2 mentions for INVO Fertility. INVO Fertility's average media sentiment score of 1.87 beat Gaxos.ai's score of 0.95 indicating that INVO Fertility is being referred to more favorably in the media.

Company Overall Sentiment
INVO Fertility Very Positive
Gaxos.ai Positive

Summary

Gaxos.ai beats INVO Fertility on 9 of the 16 factors compared between the two stocks.

Get Gaxos.ai News Delivered to You Automatically

Sign up to receive the latest news and ratings for GXAI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GXAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GXAI vs. The Competition

Export
MetricGaxos.aiHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$8.98M$9.80B$7.05B$13.10B
Dividend YieldN/A2.55%2.57%10.45%
P/E Ratio-1.6635.17269.0825.28
Price / Sales1.594.77604.1291.83
Price / CashN/A124.3470.4850.90
Price / Book0.363.9412.916.24
Net Income-$3.90M$309.96M$3.45B$347.60M
7 Day Performance-2.35%0.09%1.10%1.06%
1 Month Performance-23.15%-0.33%1.32%0.81%
1 Year Performance-22.79%19.52%62.43%20.90%

Gaxos.ai Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GXAI
Gaxos.ai
1.4087 of 5 stars		$0.83
-34.1%		N/A-24.5%$8.98M$3.72MN/A3
MGRX
Mangoceuticals
0.6665 of 5 stars		$0.53
-2.4%		N/A-66.2%$9.15M$460KN/A3
BMGL
Basel Medical Group
0.9717 of 5 stars		$4.51
-9.6%		N/A-78.1%$7.04M$8.90MN/A36
AIDX
20/20 Biolabs
2.7768 of 5 stars		$0.46
+6.0%		$5.00
+984.6%		N/A$5.65M$1.84MN/A14
NIVF
NewGenIvf Group
2.9196 of 5 stars		$0.52
+0.7%		N/A-99.8%$3.10M$4.73MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GXAI) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel